

**Notice of References Cited**

Application/Control No.

10/506,408

Applicant(s)/Patent Under  
Reexamination  
NATH ET AL.

Examiner

Jeffrey S. Parkin, Ph.D.

Art Unit

1648

Page 1 of 1

**U.S. PATENT DOCUMENTS**

*		Document Number	Date	Name	Classification
		Country Code-Number-Kind Code	MM-YYYY		
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number	Date	Country	Name	Classification
		Country Code-Number-Kind Code	MM-YYYY			
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*	Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)				
	U	Buanec, H. L., et al., 2001, Induction in mice of anti-Tat mucosal immunity by the intranasal and oral routes, Biomed. Pharmacother. 55:316-320.			
	V	Cui, Z., and R. J. Mumper, 2002, Coating of cationized protein on engineered nanoparticles results in enhanced immune responses, Intl. J. Pharmaceutics 238:229-239.			
	W	Vives, E., et al., 1994, Effects of the Tat basic domain on human immunodeficiency virus type 1 transactivation, using chemically synthesized Tat protein and Tat peptides, J. Virol. 68(5):3343-3353.			
	X	Rossi, C., et al., 1997, Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients, Gene Therapy 4:1261-1269.			

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a))  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.